Faculty

Kristopher R. Bosse, MD

Assistant Professor of Pediatrics

Department: Pediatrics

Graduate Group Affiliations

Cell and Molecular Biology

Contact information

Children's Hospital of Philadelphia
3501 Civic Center Boulevard, CTRB 3050
Philadelphia, PA 19104

Office: 651-492-6726
Fax: 267-426-0685

Email:
bossek@email.chop.edu

Education:
BA (Biochemistry )
Bowdoin College, 2002.
MD (Medicine)
University of Pennsylvania Perelman School of Medicine, 2010.

Permanent link

> Perelman School of Medicine > Faculty > Details

Selected Publications

Foster JB, Bosse KR, Griffin C, Stern A, Brimley C, Storm PB, Barrett D, Maris JMM, Resnick AC: Use of mRNA CAR T cells for malignant pediatric brain tumors. Present at the American Society of Pediatric Hematology Oncology (ASPHO) Annual Meeting April 2021.

Heitzeneder S, Bosse KR, Zhongyu Z, Dontcho J, Dhingra S, Majzner RG, Sotillo E, Buongervino S, Xu P, Huang J, Delaidelli A, Hasselblatt M, Parker K, Anbunathan H, Alag A, Hwang J, Huang M, Klysz DD, Theruvath JL, Vilches-Moure JG, Satpathy AT, Sorensen PH, Dimitrov DS, Maris JM, Mackall CM. : Potent activity of CAR T cells targeting the oncofetal protein GPC2 engineered to recognize low antigen density in neuroblastoma. American Association of Cancer Research (AACR) Annual meeting April 2021.

Pascual-Pasto G, Buongervino SN, Zhelev DV, Erbe AK, Sondel P, Dimitrov D, Bosse KR : The antibody-drug conjugate D3-GPC2-PBD induces immunogenic cell death and triggers antitumor immune responses in preclinical neuroblastoma models Advances in Neuroblastoma Research Congress January 2021.

Raman S, Buongervino SN, Lane M, Zhelev DV, Zhu Z, Cui H, Martinez B, Martinez D, Wang Y, Upton K, Patel K, Rathi KS, Pawel B, Dimitrov DS, Maris JM, Julien J-P, Bosse KR : The antibody drug conjugate D3-GPC2-PBD is potently efficacious against diverse preclinical models of neuroblastoma and other cancers via engagement of a tumor-specific conformational GPC2 epitope Advances in Neuroblastoma Research Congress January 2021.

Buongervino S, Lane M, Garrigan E, Pascual-Pasto G, Martinez D, Zhelev DV, Dimitrov DS, Bosse KR: Defining the elements of antibody-drug conjugate efficacy in neuroblastoma. Advances in Neuroblastoma Research Congress January 2021.

Ritenour LE, Randall MP, Bosse KR, Diskin SJ.: Correction to: Genetic susceptibility to neuroblastoma: current knowledge and future directions. Cell Tissue Research Sept 2020 Notes: Online ahead of print.

Chen D, Cox J, Annam J, Weingart M, Essien G, Rathi K, Rokita JL, Khurana P, Cuya SM, Bosse KR, Pilgrim A, Li D, Maris JM, Schnepp RW: LIN28B promotes neuroblastoma metastasis and regulates PDZ binding kinase. Neoplasia 22(6): 231-241, April 2020.

Sussman RT, Rokita JL, Huang K, Raman P, Rathi KS, Martinez D, Bosse KR, Lane M, Hart LS, Bhatti T, Pawel B, Maris JM.: CAMKV is a candidate immunotherapeutic target in MYCN amplified neuroblastoma. Frontiers Oncology 10(302): 1-11, March 2020.

Bosse KR, Majzner RG, Mackall CL, Maris JM. : Immune-based approaches for the treatment of pediatric malignancies. Annual Reviews Cancer Biology 4: 535-70, March 2020.

Heitzeneder S, Bosse KR, Majzner RG, Theruvath JL, Dhingra S, Xu P, Anbunathan H, Alag A, Dimitrov DS, Sotillo E, Maris JM, Mackall CL.: CAR T-cells targeting Glypican-2 effectively eradicate representative neuroblastoma disease models in the absence of toxicity. Presented at the Emerging Cellular Therapies: Cancer and Beyond Keystone Symposia, Alberta, Canada February 2020 Notes: poster.